Comparative Study of the Expressions of Nuclear (∆EX3) and Cytoplasmic (2B) Survivins in Oral Squamous Cell Carcinoma and Oral Lichen Planus Using Real‐Time PCR
Clinical and Experimental Dental Research · 2025
DOI: 10.1002/cre2.70123 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical and Experimental Dental Research, 2025. Verfasst von Maryam Amirchaghmaghi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Oral and Maxillofacial Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Survivin, Lichen Planus, Oral, Carcinoma, Squamous Cell, Mouth Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The study was supported by the Mashhad University of Medical Sciences (992125)., Mashhad University of Medical Sciences.
Abstract (Originalsprache)
Objective
Survivin is used to determine the prognosis and clinical features of premalignant and malignant lesions. The aim of this study was to determine the correlation between the expression of survivin isoforms and clinical outcomes in oral lichen planus and oral squamous cell carcinoma. Materials and Methods This cross‐sectional study examined 119 cases, including oral squamous cell carcinoma (SCC), oral lichen planus (OLP), and healthy margins of lesions. For all lesions, survivin expression was assessed quantitatively and qualitatively using real‐time polymerase chain reaction. The data were analyzed using SPSS 20.
Results
The expression of survivin‐∆EX3 and survivin‐2B were quantitatively and qualitatively higher in SCC and OLP cases than in healthy mucosa ( p < 0.05). The mean expression of survivin‐∆EX3 in erosive OLP (4.95 ± 4.41) was higher than that in nonerosive OLP (2.13 ± 3.32, p < 0.05). Moreover, the mean expression of both genes was significantly higher in different grades of SCC compared to healthy mucosa ( p < 0.05). There was also a significant correlation between gene expressions ( p < 0.001).
Conclusion
The increased expression of survivin‐∆EX3 and survivin‐2B in OSCC correlates with tumor progression and advanced clinical stages, suggesting a potential prognostic role.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oral and Maxillofacial Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- Dental Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Oral and Maxillofacial Medicine, School of Dentistry, Kerman university of Medical Science, Kerman, Iran.
ORCID-Profile: Maryam Amirchaghmaghi, Atessa Pakfetrat, Nooshin Mohtasham, Farnaz Mohajertehran, Mohammad Taghi Shakeri, Elahe Vazavandi
Förderung
- The study was supported by the Mashhad University of Medical Sciences (992125).
- Mashhad University of Medical Sciences
Zitieren
APA
Amirchaghmaghi, M., Pakfetrat, A., Mohtasham, N., Mohajertehran, F., Shakeri, M. T., & Vazavandi, E. (2025). Comparative Study of the Expressions of Nuclear (∆EX3) and Cytoplasmic (2B) Survivins in Oral Squamous Cell Carcinoma and Oral Lichen Planus Using Real‐Time PCR. Clinical and Experimental Dental Research. https://doi.org/10.1002/cre2.70123
Vancouver
Amirchaghmaghi M, Pakfetrat A, Mohtasham N, Mohajertehran F, Shakeri MT, Vazavandi E. Comparative Study of the Expressions of Nuclear (∆EX3) and Cytoplasmic (2B) Survivins in Oral Squamous Cell Carcinoma and Oral Lichen Planus Using Real‐Time PCR. Clinical and Experimental Dental Research. 2025. doi:10.1002/cre2.70123
BibTeX
@article{Amirchaghmaghi2025,
author = {Amirchaghmaghi, Maryam and Pakfetrat, Atessa and Mohtasham, Nooshin and Mohajertehran, Farnaz and Shakeri, Mohammad Taghi and Vazavandi, Elahe},
title = {Comparative Study of the Expressions of Nuclear (∆EX3) and Cytoplasmic (2B) Survivins in Oral Squamous Cell Carcinoma and Oral Lichen Planus Using Real‐Time PCR},
journal = {Clinical and Experimental Dental Research},
year = {2025},
doi = {10.1002/cre2.70123}
}
EUVIMED